NASDAQ:EQRX

EQRx (EQRX) Stock Forecast, Price & News

$1.79

-0.06 (-3.24%)

(As of 05:21 PM ET)

Compare

Today's Range: $1.76
▼
$1.88
50-Day Range: $1.61
▼
$1.96
52-Week Range: $1.58
▼
$6.05

Volume: 976,263 shs
Average Volume: 2.42 million shs
Market Capitalization: $872.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.57

EQRx MarketRank™ Forecast

Analyst Rating: Hold
1.67 Rating Score
Upside/Downside: 155.1% Upside
$4.57 Price Target
Short Interest: Bearish
7.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.57) to ($0.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

564th out of 981 stocks

Pharmaceutical Preparations Industry

271st out of 479 stocks

2.8

Analyst's Opinion

Consensus Rating
EQRx has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $4.57, EQRx has a forecasted upside of 155.1% from its current price of $1.79.
Amount of Analyst Coverage
EQRx has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.01% of the float of EQRx has been sold short.
Short Interest Ratio / Days to Cover
EQRx has a short interest ratio ("days to cover") of 8.6.
Change versus previous month
Short interest in EQRx has recently decreased by 3.97%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
EQRx does not currently pay a dividend.
Dividend Growth
EQRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EQRX.

3.3

News and Social Media Coverage

News Sentiment
EQRx has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for EQRx this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added EQRx to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, EQRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.30% of the stock of EQRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.61% of the stock of EQRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for EQRx are expected to decrease in the coming year, from ($0.57) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of EQRx is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of EQRx is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
EQRx has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About EQRx (NASDAQ:EQRX) Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

EQRX Stock News Headlines

June 2, 2023 | americanbankingnews.com

EQRx (NASDAQ:EQRX) Stock Price Up 3.6%

May 25, 2023 | americanbankingnews.com

EQRx (NASDAQ:EQRX) Trading Down 4.9%

June 8, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 19, 2023 | seekingalpha.com

CStone Breaks Up With Drugs Partner As U.S. Rollout Stalls

May 10, 2023 | msn.com

The World Has Its Way With EQRx

May 9, 2023 | finance.yahoo.com

Q1 2023 EQRx Inc Earnings Call

May 9, 2023 | markets.businessinsider.com

EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce

May 8, 2023 | seekingalpha.com

EQRx, Inc. (EQRX) Q1 2023 Earnings Call Transcript

June 8, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 8, 2023 | msn.com

EQRx GAAP EPS of -$0.17 misses by $0.03

May 8, 2023 | finance.yahoo.com

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

May 8, 2023 | finance.yahoo.com

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

May 7, 2023 | americanbankingnews.com

EQRx (EQRX) Scheduled to Post Quarterly Earnings on Monday

May 5, 2023 | msn.com

Earnings Outlook For EQRx

April 27, 2023 | finance.yahoo.com

EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

April 21, 2023 | technews.tmcnet.com

EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

April 12, 2023 | americanbankingnews.com

EQRx (NASDAQ:EQRX) Trading Down 4.8%

April 5, 2023 | msn.com

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

March 24, 2023 | americanbankingnews.com

EQRx (NASDAQ:EQRX) Stock Price Down 3.3%

March 13, 2023 | marketwatch.com

EQRx Chief Financial Officer Jami Rubin Resigns >EQRX

February 24, 2023 | bizjournals.com

Company founded to make 'radically' cheap drugs lays off 66

February 23, 2023 | finance.yahoo.com

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

February 23, 2023 | msn.com

EQRx GAAP EPS of -$0.05 beats by $0.14

February 23, 2023 | finance.yahoo.com

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

February 13, 2023 | msn.com

EQRx, Inc. (EQRX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

January 3, 2023 | finance.yahoo.com

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 20, 2022 | insidermonkey.com

5 Best Affordable Stocks to Buy Under $5

See More Headlines

EQRX Price History

30 days | 90 days | 365 days | Advanced Chart

EQRX Company Calendar

Last Earnings: 5/08/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EQRX
CUSIP: N/A
CIK: 1843762
Web: iii.cmlifesciencesspac.com
Phone: 617-315-2255
Fax: N/A
Employees: 240
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.57
High Stock Price Forecast: $5.50
Low Stock Price Forecast: $3.20
Forecasted Upside/Downside: +155.1%
Consensus Rating: Hold
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-169,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -19.03%
Return on Assets: -17.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.63
Quick Ratio: 22.63

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.90 per share
Price / Book: 0.62

Miscellaneous

Outstanding Shares: 487,360,000
Free Float: 398,172,000
Market Cap: $872.37 million
Optionable: Optionable
Beta: 0.57

Key Executives

Mr. Alexis A. Borisy A.M. (Age 51)
Founder & Exec. Chairman of Board of Directors
Comp: $858.22k

Ms. Melanie I. Nallicheri (Age 54)
CEO & Director
Comp: $832k

Ms. Jamilu E. Rubin (Age 59)
Chief Financial Officer
Comp: $479.57k

Dr. Eric E. Hedrick M.D. (Age 58)
Chief Physician Exec.
Comp: $575.1k

Mr. Robert Forrester LL.B. (Age 59)
Co-Founder & Advisor

Dr. Peter B. Bach M.D. (Age 58)
MAPP, Co-Founder & Advisor

Sir Andrew Dillon CBE
Co-Founder & Advisor

Mr. Daniel Hoey (Age 56)
Chief of Technical Operations

Ms. Dina Ciarimboli J.D. (Age 54)
Gen. Counsel & Corp. Sec.

Ms. Rona Anhalt (Age 58)
Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

EQRX Stock - Frequently Asked Questions

Should I buy or sell EQRx stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EQRx in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EQRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EQRX, but not buy additional shares or sell existing shares.
View EQRX analyst ratings or view top-rated stocks.
What is EQRx's stock price forecast for 2023?: 3 Wall Street analysts have issued 1 year target prices for EQRx's stock. Their EQRX share price forecasts range from $3.20 to $5.50. On average, they expect the company's share price to reach $4.57 in the next year. This suggests a possible upside of 155.1% from the stock's current price.
View analysts price targets for EQRX or view top-rated stocks among Wall Street analysts.
How have EQRX shares performed in 2023?: EQRx's stock was trading at $2.46 on January 1st, 2023. Since then, EQRX stock has decreased by 27.2% and is now trading at $1.79.
View the best growth stocks for 2023 here.
When is EQRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our EQRX earnings forecast.
How were EQRx's earnings last quarter?: EQRx, Inc. (NASDAQ:EQRX) announced its earnings results on Monday, May, 8th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.05.
What ETFs hold EQRx's stock?: ETFs with the largest weight of EQRx (NASDAQ:EQRX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).

What is EQRx's stock symbol?: EQRx trades on the NASDAQ under the ticker symbol "EQRX."
Who are EQRx's major shareholders?: EQRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (5.05%), Softbank Group CORP. (4.44%), BlackRock Inc. (3.28%), State Street Corp (2.90%), Arboretum Ventures LLC (2.85%) and Geode Capital Management LLC (0.90%).
How do I buy shares of EQRx?: Shares of EQRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is EQRx's stock price today?: One share of EQRX stock can currently be purchased for approximately $1.79.
How much money does EQRx make?: EQRx (NASDAQ:EQRX) has a market capitalization of $872.37 million. The company earns $-169,090,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.
How many employees does EQRx have?: The company employs 240 workers across the globe.
How can I contact EQRx?: EQRx's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is iii.cmlifesciencesspac.com. The company can be reached via phone at 617-315-2255 or via email at investors@eqrx.com.

This page (NASDAQ:EQRX) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial